US-based polymer materials and services provider Avient has added two solutions to its MEVOPUR medical-grade materials line.
The sustainable MEVOPUR products are colour and additive masterbatches based on bio-derived polyethylene (PE) and chemical foaming agents.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The products are expected to help companies manufacturing pharmaceutical packaging and medical devices to meet their sustainability targets easily.
In addition, companies using MEVOPUR medical-grade materials can also reduce their risk of regulatory non-compliance.
Avient’s MEVOPUR medical-grade materials comply with International Organisation of Standards (ISO) 13485-2016 protocols and are tested to ISO 10993-1, US Pharmacopoeia, European Pharmacopoeia and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3D guidelines.
The PE-based colour and additive masterbatches are produced using non-fossil feedstocks and have up to 95% bio-based content.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe resins serve as exact replacements for fossil-based colour concentrates and can be processed and recycled in the same way as conventional fossil-based polyolefins.
Avient launched the MEVOPUR products at the Pharmapack Europe conference, which was held at the Paris Expo Porte de Versailles this week.
The company has also introduced bio-derived, pre-coloured formulations suitable for customers who prefer ready-to-use solutions.
Also being added to the MEVOPUR range are medical-grade foaming agents designed primarily for use in polyolefins, styrenics and copolymers.
These products have been made according to MEVOPUR protocols and are claimed to offer rapid cycling, process-energy and material savings benefits to the user.
Avient is a founding member of the Alliance to End Plastic Waste and employs around 8,400 people in total.
This year, the company expects to record revenues of between $4.6bn and $4.7bn.
Earlier this month, Japanese pharmaceutical company Astellas Pharma began using biomass-based plastics in blister packages for its pharmaceutical products.
The packaging is made from plant-derived materials, with sugarcane accounting for 50% of the raw material used in its development.
